Biggest News Aggregation in the World
๐Ÿ“ฐ Term Development News

Page 25 - Term Development News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Term Development. Real-time updates on events, politics, business and more.

Insider Buying: Capstone Power Corp (TSE:RDZ) Director Buys 5,000 Shares of Stock

Capstone Power Corp (TSE:RDZ – Get Free Report) Director Whitney George acquired 5,000 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was purchased at an average cost of C$42.20 per share, with a total value of C$211,021.50. Capstone Power Stock Performance Capstone Power Corp has a one year low […]
Whitney George Sprott Power Corp Term Development First Asset Powergen Fund Capstone Power Corp Get Free Report
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

CSPAN3 Key Capitol Hill Hearings June 30, 2016

Mr. Ambassador, in the run up to the recent u. S. China strategic and economic dialogue, there were a lot of press reports of the several issues that would be on the table. One of those included the ongoing solar panel dispute and resulting poly silicone tariffs from china. However in the fact sheets that came out, theres emphasis on steel and some of the other issues. But i saw no mention of the solar issue. I was just wondering if you could give us a status report on where that stands. Thank y...
West Bank France General South China Sea Brunei General United States West Point

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated...
New Haven United States Eric Watsky Term Development Rallybio Corporation Nasdaq Exchange Commission

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcu

-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing ---- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis ---- Company Announces Extension of Runway to 3Q 2025 As Part of Po...
New Haven United States Eric Watsky Hannah Deresiewicz Jorge Gaeta Stern Investor Relations Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science